View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. News
March 22, 2022

NeuroSense to commence Phase I trial of ALS combo therapy

The trial will analyse the effect of food on bioavailability of PrimeC versus ciprofloxacin plus celecoxib in healthy adults.

NeuroSense Therapeutics is set to commence a Phase I pharmacokinetic study of its combination therapy, PrimeC, for amyotrophic lateral sclerosis (ALS) in healthy adult subjects in the US.

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

The move comes after the company obtained clearance for its Investigational New Drug application (IND) from the US Food and Drug Administration (FDA).

A new extended-release oral formulation, PrimeC consists of a fixed-dose cocktail of ciprofloxacin and celecoxib drugs, which are approved by the FDA. 

It can synergistically act on various crucial mechanisms of ALS that cause degeneration of motor neurons, inflammation, build-up of iron and impaired regulation of ribonucleic acid (RNA). 

This approach potentially aids in hindering ALS progression.

The randomised, open-label, single-dose, three treatment, three-period crossover pharmacokinetic trial will analyse the effect of food on PrimeC’s bioavailability versus bioavailability of ciprofloxacin plus celecoxib in 12 healthy adult participants.

A Phase IIa trial of PrimeC concluded recently had met the safety and efficacy endpoints including lowering functional and respiratory deterioration.

PrimeC also offered statistically significant changes in ALS-associated biological markers signifying the oral therapy’s biological activity. 

The company intends to commence a multinational, double-blind, placebo-controlled Phase IIb trial of an optimised dose and updated formulation of PrimeC in the second quarter of this year. 

NeuroSense CEO Alon Ben-Noon said: “Data from our Phase IIa clinical study confirmed that PrimeC is a novel therapy with the potential to help people with ALS and address a $3bn market in need of a more effective treatment. 

“As we prepare to initiate our Phase IIb study in the next few months, the goal of our pharmacokinetic study under FDA IND is to generate additional data on the bioavailability of PrimeC as it relates to food intake in healthy individuals.”

An incurable neurodegenerative ailment, ALS leads to complete paralysis and death within two to five years of diagnosis. 

Related Companies

Free Whitepaper
img

Unlocking the clinical trial potential of Africa

Ongoing improvements around infrastructure, continued investment, and being home to one of the world’s largest working age populations, means that Africa’s role in the clinical trials market has transformed. In this whitepaper, Oximio outlines the dynamics of today’s clinical trial market in Africa, including the key challenges the region is facing and how sponsors can overcome them to unlock the continent’s growing potential.
by Oximio
Enter your details here to receive your free Whitepaper.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. Key drug pipeline and competitive landscape changes based on the latest clinical activity, sent every Tuesday. Curated analysis and data-driven insights on clinical trials strategy and operations, sent every Thursday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU